Ecolab Stock (NYSE:ECL), Trade Ideas

Ecolab

Ecolab produces and markets cleaning and sanitation products for the industrial manufacturing, hospitality, healthcare, and life sciences markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. Additionally, Ecolab sells customized water management solutions across its end markets. The company has a strong hold on the U.S. market and is growing its presence abroad.

Earnings

News

Health Care

Markets

Trading Ideas

General

IDXX

West Pharmaceutical Services, Inc. (NYSE: WST) reported first-quarter 2024 adjusted earnings per share (ETF:EPS) of $1.56, which beat the Zacks Consensus Estimate by 20.9%. The bottom line, however, was down 21.2% year over year.

West Pharmaceutical Q1 Earnings Beat, HVP Sales Weak

Air Products and Chemicals, Inc. (NYSE: APD) has announced plans to establish a network of permanent, commercial-scale multi-modal hydrogen refueling stations spanning from Edmonton to Calgary, Alberta, Canada.


Air Products to Build Hydrogen Refueling Station Network

Businessman.Market.Ahead.Shutterstock

Analyst Color

Equities

Upgrades

Price Target

Analyst Ratings

Ecolab receives a bullish boost as Mizuho analyst John Roberts upgrades its shares from Neutral to Buy, elevating the price target to $260 from $216. Roberts notes ECL&#39;s return to historical performance trends, with nearly 25 years of meeting or surpassing quarterly estimates pre-pandemic.

Ecolab Returning As A Consistent Earnings Compounder, Says Analyst

Ecolab Inc

Ecolomondo Corp

First Trust EIP Carbon Impact ETF

ECLIPSE BANCORP INC by Eclipse Bancorp Inc.

<p><strong>West Pharmaceutical Services, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wst#NYSE">WST</a>) reported first-quarter 2024 adjusted earnings per share (ETF:EPS) of $1.56, which beat the Zacks Consensus Estimate by 20.9%. The bottom line, however, was down 21.2% year over year.</p>
<p>The adjustments include expenses related to the amortization of acquisition-related intangible assets.</p>
<p>GAAP EPS for the quarter was $1.55, down 16.2% year over year.</p>
<p>The company&#39;s shares have risen 8.1% in the past year compared with the industry&#39;s growth of 4.9%. The broader S&amp;P 500 Index has increased 25.5% in the same time frame.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/84/65685.jpg?v=1798402361" /><br />
Image Source: Zacks Investment Research</p>
<h3>Revenues in Detail</h3>
<p>West Pharmaceutical registered net sales of $695.4 million in the first quarter, down 3% year over year. The figure, however, beat the Zacks Consensus Estimate by 3.3%.</p>
<p>The company recorded an organic net sales decline of 3% in the reported quarter.</p>
<p>Per management, the top-line decline was driven by Proprietary Products&#39; lower high-value product (HVP) sales and weak Generic product sales. However, higher Contract Manufacturing component sales and continued demand for NovaPure and self-injection device platforms partially offset the decline.</p>
<h3>Segmental Details</h3>
<p>West Pharmaceutical operates under two segments &mdash; Proprietary Products and Contract-Manufactured Products.</p>
<p>Net sales in the Proprietary Products segment were $559.5 million, indicating a decline of 4% year over year as well as on an organic basis. HVP net sales, which accounted for approximately 72% of the segment&#39;s net sales, registered an organic decline of low-single-digit percentage points.</p>
<p>The Pharma market units of the Proprietary Products segment reflected a high-single-digit percentage point organic decline in the first-quarter sales. The Generic market unit registered a double-digit percentage point decline in sales. However, low-single-digit organic sales growth for the Biologics market unit partially offset the decline in the Pharma and Generic market units.</p>
<p>Product-wise, the company witnessed continued growth for its NovaPure and self-injection device platforms, along with higher sales for Daikyo Crystal Zenith components, which were more than offset by declines in FluroTec, Westar and standard components.</p>
<p>Net sales in the Contract-Manufactured Products segment increased 1.8% year over year to $135.9 million. Currency translation was a tailwind, boosting sales growth by 50 basis points. The segment saw a 1.3% improvement in organic net sales.</p>
<h3>Margins</h3>
<p>In the quarter under review, West Pharmaceutical&#39;s gross profit decreased 15.1% to $230.2 million. The gross margin contracted nearly 480 basis points (bps) to 33.1%.</p>
<p>Selling, general and administrative expenses rose 0.8% to $86.7 million. Research and development expenses went up 2.9% year over year to $17.6 million.</p>
<p>Adjusted operating profit totaled $123 million, indicating a decrease of 25.4% from the prior-year quarter&#39;s level. The adjusted operating margin contracted 530 bps to 17.7%.</p>
<h3>Financial Position</h3>
<p>West Pharmaceutical exited first-quarter 2024 with cash and cash equivalents of $601.8 million compared with $853.9 million at the end of the fourth quarter. Total debt at the end of the reported quarter was $206.2 million compared with $206.8 million at the end of the previous quarter.</p>
<p>Cumulative net cash flow from operating activities totaled $118.2 million compared with $138.1 million in the year-ago period.</p>
<h3>2024 Guidance</h3>
<p>WST raised its 2024 outlook for earnings but maintained the same for revenues.</p>
<p>It projects adjusted EPS in the range of $7.63-$7.88 for full-year 2024, compared with the previous guidance of $7.50-$7.75. The Zacks Consensus Estimate for the same is pegged at $7.62.</p>
<p>Net sales are projected between $3 billion and $3.025 billion. The Zacks Consensus Estimate for the same is pegged at $3.01 billion. The company expects currency translation to have a positive impact of $8 million on revenues. The organic sales growth estimate is 2-3%.</p>
<h3>Our Take</h3>
<p>West Pharmaceutical exited the first quarter of 2024 with better-than-expected results. The recovery in organic growth is encouraging. However, lower COVID-related sales continue to hurt the top line. The company&#39;s lower-than-market revenue outlook reflects the same. Moreover, contractions in the operating margin do not bode well.</p>
<p>On a positive note, demand for West Pharmaceutical&#39;s HVP products continued to be strong. Robust organic net sales growth in the Pharma, Biologics and Generic market units, excluding COVID-related sales, is another quarterly highlight.</p>
<div class="chart_embed">
<h3>West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise</h3>
<p><a href="https://www.zacks.com/stock/chart/WST/price-consensus-eps-surprise-chart?icid=chart-WST-price-consensus-eps-surprise-chart"><img alt="West Pharmaceutical Services, Inc. Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/58/1714051965.png" style="height:265px; width:581px" title="" /> </a></p>
<p>West Pharmaceutical Services, Inc. price-consensus-eps-surprise-chart | West Pharmaceutical Services, Inc. Quote</p>
</div>
<h3>Zacks Rank and Stocks to Consider</h3>
<p>Currently, West Pharmaceutical carries a Zacks Rank #3 (Hold).</p>
<p>Some better-ranked stocks in the broader medical space are <strong>IDEXX Laboratories, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idxx#NASDAQ">IDXX</a>), <strong>Becton, Dickinson and Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bdx#NYSE">BDX</a>), popularly known as BD, and <strong>Ecolab Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>).</p>
<p>IDEXX, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 11.6%. IDXX&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.3%.&nbsp;</p>
<p>IDEXX&#39;s shares have risen 2.9% compared with the industry&#39;s 3.9% growth in the past year.</p>
<p>BD, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 9.4%. BDX&#39;s earnings surpassed estimates in three of the trailing four quarters and met once, delivering an average surprise of 4.6%.</p>
<p>BD&#39;s shares have lost 11.1% against the industry&#39;s 4.9% growth in the past year.</p>
<p>Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 1.7%.</p>
<p>Ecolab&#39;s shares have rallied 33.8% against the industry&#39;s 9.3% decline in the past year.</p>
<p><a href="https://www.zacks.com/stock/news/2262524/west-pharmaceutical-wst-q1-earnings-beat-hvp-sales-weak?cid=CS-BENZ-FT-analyst_blog|earnings_article-2262524">To read this article on Zacks.com click here.</a></p>


<p><strong>Air Products and Chemicals, Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/apd#NYSE">APD</a>) has announced plans to establish a network of permanent, commercial-scale multi-modal hydrogen refueling stations spanning from Edmonton to Calgary, Alberta, Canada.<br />
The permanent, multi-modal hydrogen filling stations will be designed to serve both heavy-duty vehicles, such as commercial and municipal trucks and buses, and light-duty hydrogen fuel cell cars. The stations will be located along the Queen Elizabeth II Highway, which runs through Calgary and Edmonton, offering a filling experience and speed comparable to gasoline or diesel. This hydrogen infrastructure will assist Western Canada in achieving its goal of 5,000 hydrogen or dual-fuel vehicles on the road within five years.<br />
The first Air Products permanent hydrogen filling station, located in Edmonton near the construction site of the company&#39;s landmark net-zero hydrogen energy complex, is set to be onstream in 2025. Air Products has currently installed a temporary hydrogen mobile fueler on-site to supply customers. The permanent Edmonton hydrogen refueling station is partially funded with C$1 million from Natural Resources Canada&#39;s Zero Emission Vehicle Infrastructure Program.<br />
Moreover, Air Products has a hydrogen mobile fueler at Edmonton International Airport to supply hydrogen to the airport&#39;s fleet of Toyota Mirai hydrogen fuel cell vehicles, as well as a mobile fueler on Aurum Road to serve the greater Edmonton market.<br />
Air Products, the world&#39;s leading provider of hydrogen, has hands-on operational expertise with over 250 hydrogen filling station projects in 20 countries, and its technologies are used in more than 1.5 million fuelling operations each year.<br />
The stock has lost 19.4% over the past year compared with a 5.8% decline of its industry.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/0d/65605.jpg?v=970969152" /><br />
Image Source: Zacks Investment Research</p>
<p>Air Products, on its fiscal first-quarter call, said that it expects fiscal 2024 adjusted EPS of $12.20-$12.50, indicating 6-9% growth from the prior year&#39;s adjusted EPS. For the second quarter of fiscal 2024, the company expects adjusted earnings per share in the range of $2.60-$2.75.<br />
Air Products expects capital expenditures in the range of $5 billion to $5.5 billion for fiscal 2024.</p>
<div class="chart_embed">
<h3>Air Products and Chemicals, Inc. Price and Consensus</h3>
<h3><a href="https://www.zacks.com/stock/chart/APD/price-consensus-chart?icid=chart-APD-price-consensus-chart"><img alt="Air Products and Chemicals, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/8b/1713948385.png" style="height:265px; width:591px" title="" /> </a></h3>
<p>Air Products and Chemicals, Inc. price-consensus-chart | Air Products and Chemicals, Inc. Quote</p>
</div>
<h3>Zacks Rank &amp; Key Picks</h3>
<p>Air Products currently carries a Zacks Rank #3 (Hold).<br />
Better-ranked stocks in the basic materials space include <strong>Denison Mines Corp. </strong>(AMEX:DNN), <strong>Carpenter Technology Corporation </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crs#NYSE">CRS</a>) and <strong>Ecolab Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>).<br />
Denison Mines sports a Zacks Rank #1 (Strong Buy). DNN beat the Zacks Consensus Estimate in each of the last four quarters, with the average earnings surprise being 300%. The company&#39;s shares have soared 95.1% in the past year.Carpenter Technology currently carries a Zacks Rank #2 (Buy). CRS beat the Zacks Consensus Estimate in three of the last four quarters while matching it once, with the average earnings surprise being 12.2%. The company&#39;s shares have soared 60.5%% in the past year.<br />
The Zacks Consensus Estimate for Ecolab&#39;s current-year earnings is pegged at $6.43 per share, indicating a year-over-year rise of 23.4%. ECL, a Zacks Rank #2 stock, beat the consensus estimate in each of the last four quarters, with the average earnings surprise being 1.7%. The company&#39;s shares have rallied roughly 31.3% in the past year.</p>
<p><a href="https://www.zacks.com/stock/news/2260781/air-products-apd-to-build-hydrogen-refueling-station-network?cid=CS-BENZ-FT-analyst_blog|company_news_-_corporate_actions-2260781">To read this article on Zacks.com click here.</a></p>


<p>Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) has outperformed the market over the past 20 years by 2.82% on an annualized basis producing an average annual return of 10.47%. Currently, Ecolab has a market capitalization of $62.47 billion. </p>
<p><strong>Buying $100 In ECL:</strong> If an investor had bought $100 of ECL stock 20 years ago, it would be worth <strong>$752.41</strong> today based on a price of $218.50 for ECL at the time of writing.</p>
<h3>Ecolab's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1713537059_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today

<p><strong>Mizuho&nbsp;</strong>analyst John Roberts upgraded the shares of&nbsp;<strong>Ecolab Inc&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) from Neutral to Buy and&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/ECL/analyst-ratings" rel="noreferrer noopener">raised the price target from $216 to $260.</a></p>
<p>According to the analyst, ECL appears back to its historical beat-and-raise visibility.</p>
<p>The analyst noted that the company had almost 25 years of meeting or exceeding quarterly consensus estimates before the pandemic. Meanwhile, the analyst added that ECL is not resilient against travel/hospitality collapses, which happened during the pandemic &amp; immediately post-9/11.&nbsp;</p>
<p>Greater cleanliness protects customer brands against infection outbreaks, and greater re-use of expensive utility/process water saves fresh water &amp; energy usage, said the analyst about the high-ranking ESG model of the company's operations.</p>
<p>More consistent return-to-office and recovery in Asia tourism to U.S/Europe should drive cleaning chemical growth above trend in the near-term, observed the analyst.</p>
<p>The analyst expects ECL to continue to reinvest to sustain future growth through increased digitization and A.I., so that EPS growth post-2024 should be more trend line.</p>
<p>The analyst's 2024/2025/2026 EPS estimates remain unchanged at $6.35/$7.20/$7.95.</p>
<p>The analyst sees the company returning to being a consistent earnings compounder.</p>
<p><strong>Price Action</strong>: ECL shares are trading lower by 0.39% at $219.89 on the last check Friday.</p>
<p><em>Photo via Shutterstock</em></p>


<p><strong>Orion S.A. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oec#NYSE">OEC</a>) recently broke ground on a plant in Texas that will be the sole facility in the United States producing acetylene-based conductive additives for lithium-ion batteries and other applications critical to the global transition to electrification.<br />
The location in La Porte, southeast of Houston, will generate much high-skilled employment in construction and technological areas, as well as contribute breakthrough technology to the American economy. The battery additives manufactured by Orion&#39;s facility will be extremely clean, with one-tenth the carbon footprint of other regularly used materials.<br />
The plant in La Porte will be a critical step in increasing the regional supply of conductive additives in the rapidly expanding U.S. battery market. All batteries require conductive additives. They allow for a more efficient flow of electricity and improve the life of lithium-ion batteries, the most valuable component of electric vehicles. The material is also vital in high-voltage cables used in wind and solar farms.<br />
The additives manufactured at the La Porte plant will be made from acetylene, a colorless gas that Orion&#39;s manufacturing method converts into powder of the exceptional purity required by major battery manufacturers. Equistar Chemicals LP, a LyondellBasell subsidiary, will supply the acetylene from an adjacent site.<br />
Orion&#39;s facility in La Porte is similar to one located in Berre-l&#39;Etang, southern France. LyondellBasell supplies acetylene to the site as well. The LaPorte project&#39;s major equipment procurement and off-site fabrication are already well underway. Field construction works are speeding up, and the facility is anticipated to start operations in the second quarter of 2025.<br />
Shares of OEC have lost 3.4% over the past year compared with a 7.2% decline of its industry.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6f/64862.jpg?v=212907768" /><br />
Image Source: Zacks Investment Research</p>
<h3>Zacks Rank &amp; Key Picks</h3>
<p>OEC currently carries a Zacks Rank #5 (Strong Sell).<br />
Better-ranked stocks in the basic materials space include <strong>Denison Mines Corp.</strong> (AMEX:DNN), <strong>Carpenter Technology Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crs#NYSE">CRS</a>) and <strong>Ecolab Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>).<br />
Denison Mines sports a Zacks Rank #1 (Strong Buy). DNN beat the Zacks Consensus Estimate in each of the last four quarters, with the average earnings surprise being 300%. The company&#39;s shares have soared 112.6% in the past year.<br />
Carpenter Technology currently carries a Zacks Rank #2 (Buy). CRS beat the Zacks Consensus Estimate in three of the last four quarters while matching it once, with the average earnings surprise being 12.2%. The company&#39;s shares have soared 80.8%% in the past year.<br />
The Zacks Consensus Estimate for Ecolab current-year earnings is pegged at $6.43 per share, indicating a year-over-year rise of 23.4%. ECL, a Zacks Rank #1 stock, beat the consensus estimate in each of the last four quarters, with the average earnings surprise being 1.7%. The company&#39;s shares have rallied roughly 34.4% in the past year.</p>
<p><a href="https://www.zacks.com/stock/news/2254227/orion-oec-breaks-ground-on-texas-battery-materials-plant?cid=CS-BENZ-FT-analyst_blog|company_news_-_corporate_actions-2254227">To read this article on Zacks.com click here.</a></p>


Small Cap

Orion Breaks Ground on Texas Battery Materials Plant

<p>In the last three months, 19 analysts have published ratings on Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $238.21, a high estimate of $260.00, and a low estimate of $216.00. This upward trend is evident, with the current average reflecting a 11.31% increase from the previous average price target of $214.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1712926857_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A clear picture of Ecolab's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$256.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$238.00</td>
<td>-</td>
</tr>
<tr>
<td>Pavel Molchanov</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Charles Neivert</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$260.00</td>
<td>-</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$238.00</td>
<td>-</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Seth Weber</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$232.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$227.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$237.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$238.00</td>
<td>-</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$216.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shlomo Rosenbaum</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$225.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Jeffrey Zekaukas</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$238.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$216.00</td>
<td>$185.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ecolab. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ecolab compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Ecolab's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ecolab's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ECL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ecolab analyst ratings.</strong></a></p>
<h2>About Ecolab</h2>
<p>Ecolab produces and markets cleaning and sanitation products for the industrial manufacturing, hospitality, healthcare, and life sciences markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. Additionally, Ecolab sells customized water management solutions across its end markets. The company has a strong hold on the U.S. market and is growing its presence abroad.</p>
<h3>Financial Insights: Ecolab</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Ecolab's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>7.28%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Ecolab's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>10.29%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Ecolab's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.12%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Ecolab's ROA excels beyond industry benchmarks, reaching <strong>1.85%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>1.09</strong>, Ecolab faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Ecolab Stock: A Deep Dive Into Analyst Perspectives (19 Ratings)

<p>Mizuho  analyst John Roberts   upgrades Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) from Neutral to Buy and raises the price target from $216 to $260.</p>


Mizuho Upgrades Ecolab to Buy, Raises Price Target to $260

<p>Citigroup  analyst Patrick Cunningham   maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Neutral and raises the price target from $237 to $256.</p>


Citigroup Maintains Neutral on Ecolab, Raises Price Target to $256

<p><strong>Coeur Mining, Inc.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cde#NYSE">CDE</a>) announced that its newly expanded Rochester silver and gold mine in Nevada achieved commercial production.<br />
On Mar 7, the new three-stage crushing circuit and truck load-out facility were officially commissioned. Since then, the crusher circuit has operated at an average throughput of more than 70,000 tons per day and has topped 88,000 tons per day. This led to the declaration of commercial production by the end of the first quarter.<br />
Backed by this, the company additionally stated that the ramp-up to full planned capacity of 88,000 tons per day (about 32 million tons per year) is scheduled to be completed in the first half of 2024. With commissioning completed and ramp-up progressing well, the company will be able to shift its focus to mine optimization activities and business development programs aimed at maximizing the value of this world-class, long-life asset.<br />
Once fully operational, throughput levels are estimated to be 2.5 times higher than in the past, making Rochester one of the world&#39;s largest open-pit heap leach operations. It is expected to be America&#39;s largest source of domestically produced and processed silver, as well as a key driver of CDE&#39;s cash flow growth.<br />
In the fourth quarter of 2023, the company reported an adjusted loss of 2 cents per share, whereas the Zacks Consensus Estimate was pegged at breakeven. The company recorded revenues of $262 million in the quarter.</p>
<h3>Price Performance</h3>
<p>Coeur&#39;s shares have gained 15.3% in the past year compared with the industry&#39;s 34.7% growth.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/70/64608.jpg?v=842630886" /><br />
Image Source: Zacks Investment Research</p>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
<p>Coeur currently carries a Zacks Rank #3 (Hold).<br />
Some better-ranked stocks from the basic materials space are <strong>Ecolab Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>), <strong>Carpenter Technology Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crs#NYSE">CRS</a>) and <strong>Innospec Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iosp#NASDAQ">IOSP</a>). ECL and CRS sport a Zacks Rank #1 (Strong Buy) at present, and IOSP has a Zacks Rank #2 (Buy).<br />
The Zacks Consensus Estimate for Ecolab&#39;s 2024 earnings is pegged at $6.39 per share, indicating an increase of 22.7% from the prior year&#39;s reported number. It has an average trailing four-quarter earnings surprise of 1.7%. ECL shares have gained 41.8% in a year.<br />
The Zacks Consensus Estimate for Carpenter Technology&#39;s 2024 earnings is pegged at $4 per share. The consensus estimate for 2024 earnings has moved 1% north in the past 60 days. It has an average trailing four-quarter earnings surprise of 14.3%. CRS shares have gained 33.5% in a year.<br />
The Zacks Consensus Estimate for Innospec&#39;s 2024 earnings is pegged at $6.72 per share, indicating a year-over-year rise of 10.3%. The Zacks Consensus Estimate for IOSP&#39;s current-year earnings has been revised 2% north in the past 60 days. It has an average trailing four-quarter earnings surprise of 10.5%. The company&#39;s shares have rallied 19.3% in the past year.</p>
<p><a href="https://www.zacks.com/stock/news/2252780/coeur-s-cde-rochester-mine-starts-commercial-operation?cid=CS-BENZ-FT-analyst_blog|company_news_-_corporate_actions-2252780">To read this article on Zacks.com click here.</a></p>


Penny Stocks

IOSP

Coeur's (CDE) Rochester Mine Starts Commercial Operation

<p>RBC Capital  analyst Ashish Sabadra   reiterates Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Outperform and maintains $238 price target.</p>


Reiteration

RBC Capital Reiterates Outperform on Ecolab, Maintains $238 Price Target

<p>Raymond James  analyst Pavel Molchanov   maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Outperform and raises the price target from $230 to $250.</p>


Raymond James Maintains Outperform on Ecolab, Raises Price Target to $250

<p>Shares of <strong>Ecolab Inc</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ecl#NYSE">ECL</a>) were <a href="https://www.benzinga.com/quote/ECL/">rising in early trading on Wednesday</a>.</p>
<p>The downside risk to the company&rsquo;s earnings seems &ldquo;relatively benign,&rdquo; given its business model and strategy, according to Piper Sandler.</p>
<p><strong>The Ecolab Analyst:</strong> Charles Neivert initiated coverage of Ecolab with an Overweight rating and price target of $260.</p>
<p><strong>The Ecolab Thesis:</strong> The company&rsquo;s earnings trajectory has been mostly consistent, in sharp contrast to other companies in the <a href="https://www.benzinga.com/money/best-sectors-to-invest-in-right-now/">sector</a>, which face &ldquo;substantial cyclicality,&rdquo; Neivert said in the initiation note.</p>
<p><em>Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.</em></p>
<p>Efforts to increase sustainability and reduce resource consumption &ldquo;are taking on increasing importance within the customer base and ECL has a broad range of products and services to offer, which we think allows them to increase their engagement with almost every customer it currently serves,&rdquo; the analyst stated.</p>
<p>&ldquo;Our EBITDA estimate is above the 2025 consensus estimate of $3.76B based on our slightly more constructive outlook for key end markets, the increasing value of the products and services ECL brings to its customers, which in turn drive the company&rsquo;s ability to raise prices in the future, and our belief that ECL should benefit from continuing multiple expansion as it drives its margin toward 20%,&rdquo; he added.</p>
<p><strong>ECL Price Action: </strong>Shares of Ecolab had risen by 0.26% to $228.04 at the time of publication on Wednesday.</p>
<p><em>Image: Shutterstock</em></p>


Long Ideas

Initiation

Ecolab Has 'Earnings Consistency,' Downside Risk Is 'Relatively Benign': Analyst

<p>Piper Sandler  analyst Charles Neivert   initiates coverage on Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Overweight rating and announces Price Target of $260.</p>


Piper Sandler Initiates Coverage On Ecolab with Overweight Rating, Announces Price Target of $260

<p>In the latest quarter, 15 analysts provided ratings for Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Ecolab, presenting an average target of $232.6, a high estimate of $260.00, and a low estimate of $216.00. Witnessing a positive shift, the current average has risen by 10.44% from the previous average price target of $210.62.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1711566008_0_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The perception of Ecolab by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$240.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$238.00</td>
<td>-</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Seth Weber</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$232.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$227.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$237.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$238.00</td>
<td>-</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$216.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shlomo Rosenbaum</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$225.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Jeffrey Zekaukas</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$238.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$216.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$227.00</td>
<td>$211.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ecolab. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ecolab compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Ecolab's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ecolab's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ECL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ecolab analyst ratings.</strong></a></p>
<h2>Discovering Ecolab: A Closer Look</h2>
<p>Ecolab produces and markets cleaning and sanitation products for the industrial manufacturing, hospitality, healthcare, and life sciences markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. Additionally, Ecolab sells customized water management solutions across its end markets. The company has a strong hold on the U.S. market and is growing its presence abroad.</p>
<h3>Understanding the Numbers: Ecolab's Finances</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Ecolab's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of <strong>7.28%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Ecolab's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>10.29%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Ecolab's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.12%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.85%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Ecolab's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.09</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Ecolab: Insights From 15 Analyst Reviews

<p>Morgan Stanley  analyst Vincent Andrews   maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Equal-Weight and raises the price target from $230 to $240.</p>


Morgan Stanley Maintains Equal-Weight on Ecolab, Raises Price Target to $240

<p>Friday marks the last chance for investors to receive the next  dividend payout from <strong>Ecolab</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>). </p>
<h3>What's Happening</h3>
<p>The company announced on Thursday that it would pay shareholders a quarterly dividend of 57 cents per share. On Monday, Ecolab will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 57 cents lower than it would have opened on any other day.</p>
<p>In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Monday. Shareholders who own ECL as of the end of Friday's session are eligible to receive the 57 cents dividend payout for every share that they own. </p>
<p>According to the company, this dividend will be paid out to shareholders on April 15, 2024. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. </p>
<p><a href="https://www.benzinga.com/stock//dividends">Click here</a> to find details on Ecolab's previous dividends.</p>
<p>To keep track of which companies are distributing dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.  </p>


Dividends

Friday Is Your Last Chance To Buy Ecolab Before The Dividend Payout

<p>Ecolab Inc., a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life, today announced the successful sourcing of enough clean electricity to power&nbsp;100%&nbsp;of its European operations, thanks to the completion of a windfarm project with the global renewable energy company, Low Carbon.</p>


Government

Regulations

Ecolab Achieves 100% Renewable Electricity in Europe With the Completion of Windfarm Development Project

<p><strong>Ecolab's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) short percent of float has risen 21.79% since its last report. The company recently reported that it has <strong>2.37 million shares sold short</strong>, which is 0.95% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.57 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Ecolab Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709817309_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Ecolab has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Ecolab's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Ecolab's peer group average for short interest as a percentage of float is 3.86%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Peering Into Ecolab's Recent Short Interest

<p>Throughout the last three months, 16 analysts have evaluated Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $228.12, a high estimate of $260.00, and a low estimate of $213.00. This current average reflects an increase of 9.15% from the previous average price target of $209.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709316091_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Ecolab by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Seth Weber</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Andrew Wittmann</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$232.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$227.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$237.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$238.00</td>
<td>-</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$216.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Shlomo Rosenbaum</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$225.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Jeffrey Zekaukas</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$238.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$216.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$227.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$213.00</td>
<td>-</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$213.00</td>
<td>-</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$213.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ecolab. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ecolab compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Ecolab's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ECL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Ecolab analyst ratings.</strong></a></p>
<h2>All You Need to Know About Ecolab</h2>
<p>Ecolab produces and markets cleaning and sanitation products for the industrial manufacturing, hospitality, healthcare, and life sciences markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. Additionally, Ecolab sells customized water management solutions across its end markets. The company has a strong hold on the U.S. market and is growing its presence abroad.</p>
<h3>Ecolab: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Ecolab's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>7.28%</strong> as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Ecolab's net margin excels beyond industry benchmarks, reaching <strong>10.29%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Ecolab's ROE excels beyond industry benchmarks, reaching <strong>5.12%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Ecolab's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.85%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Ecolab's debt-to-equity ratio surpasses industry norms, standing at <strong>1.09</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


16 Analysts Assess Ecolab: What You Need To Know

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><em>BNN Bloomberg </em><a href="https://www.bnnbloomberg.ca/investing/video/the-s-p-500-is-probably-about-8-per-cent-overvalued-cresset-capital-s-jack-ablin~2723985">reported</a> in July 2023 that the <strong>S&amp;P 500 </strong>was overvalued by about 8%, according to Cresset Capital Chief Information Officer Jack Ablin. In the eight months since, it&rsquo;s up another 19%, providing plenty of overvalued S&amp;P 500 stocks to avoid.&nbsp;</p>



<p>An excellent place to find these overvalued S&amp;P 500 stocks is the Magnificent Seven. The index&rsquo;s current trailing 12-month (<span>TTM</span>) price-to-earnings (P/E) ratio is <a href="https://www.barrons.com/market-data/stocks/us/pe-yields">23.6x</a>, while its forward 12-month P/E ratio is 21.6x. A year ago, the S&amp;P 500&rsquo;s TTM P/E was 18.1, 30% higher.&nbsp;Ablin did say last July that the average stock would probably perform well despite the index&rsquo;s excessive valuation. That&rsquo;s changed with the higher P/E.</p>



<p>As of March 5, 2024, the Magnificent Seven&rsquo;s TTM P/E was <a href="https://www.lpl.com/research/blog/are-magnificent-seven-valuations-warranted.html#:~:text=With%20Q4%202023%20earnings%20season,the%20broader%20S%26P%20earnings%20this">38.5x</a>, 38% lower, while the <strong>S&amp;P 500 Equal Weight Index </strong>was 20.6x, 16% cheaper than the market cap-weighted version.&nbsp;To make my list of three overvalued S&amp;P 500 stocks, it can&rsquo;t be one of the Magnificent Seven and it should have a TTM P/E higher than its current ratio of 23.6x.&nbsp;</p>



<h2>Axon Enterprise (AXON)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/axon1600-300x169.png" alt="Person holding mobile phone with logo of American weapon manufacturer Axon Enterprise Inc. on screen in front of webpage. Focus on cellphone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div><p><strong>Axon Enterprise </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/axon-stock-quote/"><strong>AXON</strong></a></span>) has a current TTM P/E of <a href="https://www.morningstar.com/stocks/xnas/axon/valuation">135.1x</a> and a forward P/E of 76.6x, both considerably higher than the index.&nbsp;The company is best known for its <a href="https://www.axon.com/">Taser</a> line of smart weapons, used by law enforcement and civilians. However, it also sells <a href="https://www.axon.com/products">body cameras</a>, software and even drones.&nbsp;&nbsp;&nbsp;&nbsp;</p>



<p><a href="https://investorplace.com/industries/industrial/defense/">Defense stocks</a> are doing okay in 2024. The <strong>iShares U.S. Aerospace &amp; Defense ETF </strong>(BATS:<span><a href="https://investorplace.com/stock-quotes/ita-stock-quote/"><strong>ITA</strong></a></span>), which has an AXON weighting of <a href="https://www.ishares.com/us/products/239502/ishares-us-aerospace-defense-etf">4.37%</a> (ninth highest in the exchange traded fund (<span>ETF</span>)), is up 6.6% year-to-date (YTD), while AXON stock is up 23.7%.&nbsp;</p>



<p>While there is no question Axon is growing sales- they were up 31% in 2023 to <a href="https://investor.axon.com/2024-02-27-Axon-2023-Revenue-Grows-31-to-1-56-Billion">$1.56 billion</a> with 22% projected growth to $1.91 billion at the midpoint of its 2024 guidance- it made just $85.4 million on a non-GAAP basis on its 2023 revenue. That&rsquo;s a net margin of 5.5%, worse than some grocery store chains.&nbsp;Fortunately, it&rsquo;s got plenty of cash to keep it going for years, but it&rsquo;s not worth $24 billion.&nbsp;</p>



<p>Regarding Wall Street, I am clearly on the other side of its valuation. Of the <a href="https://www.marketwatch.com/investing/stock/axon/analystestimates">13</a> covering its stock, nine rate it a Buy, with a $314.27 target price, about where it&rsquo;s currently trading.</p>



<h2>Dexcom (DXCM)</h2>



<a href="https://investorplace.com/wp-content/uploads/2021/08/sens_glucose_monitoring_1600.jpg"><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/sens_glucose_monitoring_1600-300x169.jpg" alt="A photo of a phone giving various medical information from an arm insertion."></a><p><strong>Dexcom </strong>(NASDAQ:<span><a href="https://investorplace.com/stock-quotes/dxcm-stock-quote/"><strong>DXCM</strong></a></span>) has a current TTM P/E of <a href="https://www.morningstar.com/stocks/xnas/dxcm/valuation">103.2x</a> and a forward P/E of 78.2x, both considerably higher than the index.</p>



<p>The San Dieg0-based company is a manufacturer of continuous glucose monitoring (<span>CGM</span>) systems like the <a href="https://provider.dexcom.com/products">Dexcom G6</a>, the &ldquo;only integrated CGM (iCGM) that can power automated insulin delivery (<span>AID</span>) systems and provide real-time glucose readings, no fingersticks or scanning required.&rdquo;</p>



<p>I last recommended its stock in September 2023 when it was trading around <a href="https://investorplace.com/2023/09/3-healthcare-stocks-that-should-be-on-every-investors-radar-this-fall/">$88</a>. I liked the fact that its international business <a href="https://investorplace.com/2023/09/3-healthcare-stocks-that-should-be-on-every-investors-radar-this-fall/">continued to grow</a>. In 2023, its international sales were just under <a href="https://investors.dexcom.com/news/news-details/2024/Dexcom-Reports-Fourth-Quarter-and-Fiscal-Year-2023-Financial-Results/default.aspx">$1 billion</a>, 30% higher than in 2022. They accounted for 28% of Dexcom&rsquo;s overall revenue, 200 basis points higher than a year earlier.&nbsp;</p>



<p>If you bought in October at its 52-week low of $74.75, you&rsquo;ve almost doubled your money in less than six months. If you&rsquo;re a buy-and-hold investor, I wouldn&rsquo;t sell, but you might consider buying a put option to protect some of your profits.&nbsp;</p>



<p>Analysts love DXCM stock. Of the <a href="https://www.marketwatch.com/investing/stock/dxcm/analystestimates">25</a> covering it, 20 rate it a Buy, with a $149 target price, 8% higher than where it&rsquo;s currently trading.&nbsp;I like the stock, but at 103x earnings, I&rsquo;d wait for an entry point below $100. Over the past five years, it&rsquo;s traded below $100 on at least three occasions.&nbsp;&nbsp;</p>



<h2>Ecolab (ECL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/07/ecl1600_ecolab-300x169.jpg" alt="Ecolab (ECL) logo on its corporate headquarters building."><div>Source: Ken Wolter / Shutterstock.com</div></div><p><strong>Ecolab </strong>(NYSE:<span><a href="https://investorplace.com/stock-quotes/ecl-stock-quote/"><strong>ECL</strong></a></span>) has a current TTM P/E of <a href="https://www.morningstar.com/stocks/xnys/ecl/valuation">47.5x</a> and a forward P/E of 35.5x, both considerably higher than the index but only slightly higher than its five-year averages for both.&nbsp;</p>



<p>In May 2023, I included Ecolab in a group of three stocks to buy that the Bill &amp; Melinda Gates Foundation Trust <a href="https://investorplace.com/2023/05/bill-gates-stocks-2023/">owned</a>. The provider of &ldquo;water, hygiene and infection prevention solutions and services&rdquo; was one of two stocks the trust added to in <a href="https://www.sec.gov/Archives/edgar/data/1166559/000110465923021739/xslForm13F_X02/infotable.xml">Q4 2022</a>. It owned 5.22 million shares of Ecolab valued at $759.5 million.&nbsp;</p>



<p>Fast forward to Q4 2023. It owned the same shares, but their value at the end of December was <a href="https://www.sec.gov/Archives/edgar/data/1166559/000110465924023662/xslForm13F_X02/infotable.xml">$1.03 billion</a>, a return of 32% in 2023. They&rsquo;re now worth $1.21 billion after just three months in 2024.&nbsp;</p>



<p>Ecolab is worth owning for the long haul. Its mission to solve some of the planet&rsquo;s most pressing issues is admirable. Although aggressive, its growth goals should be obtainable: 6-8% annual revenue growth and 15% earnings-per-share (<span>EPS</span>) growth annually. However, at 48x earnings, its valuation is nearing an all-time high. Levels like that are not sustainable in a market correction.&nbsp;</p>



<p><em>On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> Publishing Guidelines</a>.</em></p>
<div><p>Will Ashworth has written about investments full-time since 2008. Publications where he&rsquo;s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/04/3-overvalued-sp-500-stocks-for-your-do-not-buy-list/">3 Overvalued S&amp;P 500 Stocks for Your ‘Do NOT Buy' List</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

3 Overvalued S&P 500 Stocks for Your 'Do NOT Buy' List

Charles Neivert, an analyst from Piper Sandler, has initiated a new Buy rating on Ecolab (ECL). Charles Neivert has given his Buy rating due to a c...

Ecolab Endorsed with Buy Rating: Analyst Forecasts Strong Earnings and Strategic Growth

ClearBridge Dividend Strategy Q1 2024 Portfolio Manager Commentary

Dividend Champion, Contender, And Challenger Highlights: Week Of April 7

Ecolab lands a Zacks Rank #1 (Strong Buy) right now and it appears poised to possibly break out to new all-time highs. Ecolab is also an S&P 500 dividend aristocrat stock.

Buy this Surging, Top-Ranked Dividend Aristocrat Stock?

In a report released yesterday, Ashish Sabadra from RBC Capital maintained a Buy rating on Ecolab (ECL – Research Report), with a price target of $...

Ecolab (ECL): New Buy Recommendation for This Basic Materials Giant

Albemarle remains most heavily shorted materials stock in March

Albemarle remains the most heavily shorted materials stock in March

GM expected to report Q1 EPS of $2.14 on revenue of $41.88B, Ford expected to report Q1 EPS 39c on revenue of $37.62B.

Here's What Wall St. Experts Are Saying About These Automakers Ahead Of Earnings

Artisan Global Opportunities Fund Q1 2024 Commentary

AAPL

ABBNY

ABBV

ABLZF

ADDDF

ADDYY

ALLG

ALRS

ANET

AVGO

AXON

AZNCF

BANF

CACG

CCOI

CFCV

CHKEL

CHKEW

CHKEZ

CINF

CSCO

CTRE

CUBE

DXCM

EPRT

EVBN

FCPT

FFMR

FITB

FULT

GILD

GNTY

HLAN

HURC

IIPR

INFR

INTC

INTU

IROQ

JJSF

JOUT

LECO

LRGE

LULU

MDLZ

MGRC

MPWR

MSFT

NOKBF

NVDA

NWFL

NXPI

ORCL

RELX

REXR

RGCO

RLXXF

RVSB

SFBS

SIEGY

SMAWF

SNDR

SPGI

STAG

STLD

TEAM

TFII

THFF

TOWN

TSLA

TSMWF

TYBT

VWDRY

VWSYF

WASH

WDAY

XRAY

YLDE

YORW

Press Releases

Ecolab Again Ranks on CDP A Lists for Water and Climate Leadership

Ecolab Announces Strong Fourth Quarter Performance and 2024 Outlook; Reported Diluted EPS $1.41; Adjusted Diluted EPS $1.55, +22%; 2024 Adjusted Diluted EPS Outlook: $6.10 to $6.50, +17% to 25%

Ecolab Appoints Judson Althoff to Board of Directors

Ecolab Declares Cash Dividend

Ecolab Named One of the World's Most Ethical Companies for 18th Consecutive Year

Ecolab Schedules Webcast of Industry Conference for March 14, 2024

Ecolab Schedules Webcast and Conference Call on April 30th

Ecolab Watermark™ Study Reveals Global Generational Gap on Access to Clean and Safe Water